Support levels clustered around 24,900 to 25,000, but analysts cautioned that any upside movement would likely face resistance
For the fourth consecutive session, Indian equity markets retreated on Wednesday, caught between global uncertainty and domestic profit-taking — a rhythm familiar to any market that has grown cautious in the face of unresolved signals. The Nifty index clung to support near 25,040, while private banks and technology stocks led the decline, even as individual companies announced investments, regulatory wins, and governance commitments that spoke to a longer, quieter story of corporate ambition unfolding beneath the surface noise.
- Indian markets fell for a fourth straight day, with the Nifty hovering near critical support at 25,040 as sellers dominated autos, energy, metals, and especially private banks and IT stocks.
- Technical analysts warned that any recovery faces stiff resistance until banking and IT sectors stabilize, leaving the market in a fragile holding pattern between 24,900 and 25,000.
- Beneath the index-level pressure, major corporate moves unfolded — Polycab's promoters offloaded Rs 880 crore in shares, Tata Steel deepened overseas commitments with a Rs 4,054 crore subsidiary investment, and Waaree Energies bet Rs 300 crore on renewable energy storage.
- Pharmaceutical companies delivered rare bright spots, with Lupin winning tentative FDA approval for a generic HIV drug, Dr. Reddy's and Hetero Labs planning a $40-per-year HIV prevention drug by 2027, and Glenmark's subsidiary securing an exclusive cancer drug licensing deal with China's Hengrui Pharma.
- Governance and capital flows added texture to the day — Gautam Adani pledged stronger oversight following SEBI's dismissal of Hindenburg's fraud allegations, while Goldman Sachs and Morgan Stanley quietly acquired a combined 5% stake in Akzo Nobel India for nearly Rs 765 crore.
- The market's near-term fate rests almost entirely on whether banking and technology stocks can find buyers willing to step in — until then, analysts see the path of least resistance pointing downward.
Indian equity markets extended their losing streak into a fourth consecutive session on Wednesday, with the Nifty index testing support near 25,040 as investors continued trimming positions across autos, energy, and metals. Private banks and IT stocks bore the heaviest selling pressure, dragging the broader index lower even as some analysts hinted that a short-term reprieve might be approaching.
The technical landscape offered little reassurance. Support clustered between 24,900 and 25,000, but analysts cautioned that meaningful upside would remain elusive until the banking and IT sectors showed signs of stabilization — leaving the market in a cautious wait-and-see posture.
Yet beneath the index-level gloom, corporate India was anything but still. Polycab India's promoters prepared to sell 1.2 million shares at Rs 7,300 each, raising Rs 880 crore through a block deal. Tata Steel committed Rs 4,054.66 crore to its overseas subsidiary T Steel Holdings, while Waaree Energies directed Rs 300 crore into its energy storage arm through a rights issue — a quiet vote of confidence in the renewable sector.
Pharmaceutical companies generated the day's most consequential headlines. Lupin received tentative FDA approval for a generic HIV treatment, a meaningful addition to its portfolio. Dr. Reddy's Laboratories and Hetero Labs announced plans to manufacture a new HIV prevention drug at roughly $40 annually by 2027, dramatically undercutting existing prices. Glenmark's specialty subsidiary, meanwhile, signed an exclusive licensing deal with China's Hengrui Pharma to develop and commercialize a cancer drug.
Elsewhere, Goldman Sachs and Morgan Stanley joined other institutions in acquiring a combined 5% stake in Akzo Nobel India for nearly Rs 765 crore. Poly Medicure moved toward a full acquisition of Italy's Citieffe Group, and Capri Global Capital outlined plans to raise Rs 6,500 crore through bonds and loans to fund its lending book.
Gautam Adani used the moment to reaffirm governance commitments across his conglomerate, following SEBI's dismissal of fraud and manipulation allegations first raised by Hindenburg Research nearly three years ago. Reliance Industries' consumer arm announced a Rs 1,156 crore manufacturing investment in Tamil Nadu, and Newgen Software's UK subsidiary signed a five-year services agreement with TCS NV in Belgium.
For traders, the central question remained unchanged: whether technical support would hold, or whether further weakness lay ahead — an answer that, analysts agreed, depended almost entirely on what the banking and technology sectors decided to do next.
Indian equity markets slipped lower for a fourth straight session on Wednesday, caught in a familiar squeeze between global uncertainty and domestic profit-taking. The Nifty index found its first meaningful support at the 20-day exponential moving average, hovering near 25,040, as investors trimmed positions across autos, energy, and metals. Private banks and information technology stocks bore the brunt of the selling, their weakness dragging the broader index down even as some analysts suggested a temporary reprieve might be coming.
The technical picture offered little comfort. Support levels clustered around 24,900 to 25,000, but analysts cautioned that any upside movement would likely face resistance until the banking and IT sectors showed signs of stabilizing. The market's recent trajectory suggested investors were waiting for clearer signals before committing fresh capital.
Amid the broader malaise, individual stocks commanded attention for reasons beyond the day's trading action. Polycab India's promoters were preparing to offload 1.2 million shares through a block deal, pricing them at Rs 7,300 each and raising Rs 880 crore in the process. Tata Steel, meanwhile, was deepening its overseas footprint by investing Rs 4,054.66 crore into its subsidiary T Steel Holdings, acquiring 4,577 crore shares in the transaction. Waaree Energies channeled Rs 300 crore into its energy storage subsidiary through a rights issue, signaling confidence in the renewable energy storage sector even as the broader market struggled.
Pharmaceutical companies dominated the newsflow with regulatory and commercial breakthroughs. Lupin received tentative approval from the U.S. Food and Drug Administration for a generic version of an HIV treatment combining Bictegravir, Emtricitabine, and Tenofovir Alafenamide—a significant milestone for the company's generic portfolio. Dr. Reddy's Laboratories and Hetero Labs announced plans to manufacture and distribute a new HIV prevention drug at roughly $40 annually starting in 2027, undercutting existing prices substantially. Glenmark Pharma's specialty subsidiary signed an exclusive licensing agreement with China's Hengrui Pharma to develop and market a cancer drug, Trastuzumab Rezetecan.
Investment activity continued despite market headwinds. Goldman Sachs, Morgan Stanley, and other financial institutions acquired a combined 5% stake in Akzo Nobel India through open-market transactions valued near Rs 765 crore. Poly Medicure was moving toward a full acquisition of Italy's Citieffe Group at an enterprise value of Rs 324 crore. Capri Global Capital outlined plans to raise Rs 6,500 crore this fiscal year through bonds and loans to fund its lending operations.
The Adani Group made headlines when Gautam Adani committed to strengthening governance standards across his conglomerate following SEBI's dismissal of fraud and stock manipulation allegations that Hindenburg Research had leveled nearly three years earlier. Reliance Industries' consumer products arm announced a Rs 1,156 crore investment in a new integrated manufacturing facility in Tamil Nadu, joining other major FMCG players in expanding regional production capacity. SEPC secured a Rs 751.98 crore purchase order from Gefos Solutions for construction materials across four infrastructure projects. Newgen Software's UK subsidiary signed a five-year master services agreement with TCS NV in Belgium, covering cloud hosting, licensing, and implementation work.
For traders watching these names, the immediate question remained whether the market's technical support would hold or whether further weakness lay ahead. The answer, analysts suggested, depended almost entirely on whether the banking and technology sectors could arrest their decline and attract fresh buying interest.
Citas Notables
A temporary breather cannot be ruled out, with immediate support seen around 24,900–25,000, but upside likely to remain capped until private banks and IT stocks show signs of recovery— Market analysts
La Conversación del Hearth Otra perspectiva de la historia
Why did the market fall for four days straight? What triggered this?
It's a combination—global headwinds pushing down sentiment, but also domestic profit-taking. Investors were trimming positions in autos, energy, metals. The real weakness came from private banks and IT stocks, which are usually the market's anchors.
So when you say the Nifty tested support at 25,040, what does that mean for someone watching their portfolio?
It means the index found a floor—a level where enough buyers stepped in to prevent further immediate decline. But that support is fragile. The next level down is 24,900 to 25,000. If that breaks, there's real air beneath it.
Looking at all these corporate actions—Polycab selling shares, Tata Steel investing overseas, Lupin getting FDA approval—does that suggest confidence or just business as usual?
It's both. The capital moves—the investments, the acquisitions—those suggest companies still believe in their futures. But the timing matters. Polycab's promoters selling Rs 880 crore worth of shares while the market is weak? That's worth watching. Are they taking profits before things get worse, or just rebalancing?
The pharma approvals seem significant. Is that sector decoupling from the broader market?
Pharma is always its own story. An FDA approval for a generic HIV drug or a cancer drug licensing deal—those are long-term value drivers independent of whether the Nifty is up or down today. But investors need cash to buy those stories, and right now cash is moving to the sidelines.
What about the Adani governance announcement? Does that change anything?
SEBI already dismissed the Hindenburg allegations, so this is Adani signaling he's heard the skepticism and is tightening controls. It's a confidence play—reassurance that the conglomerate takes oversight seriously. Whether it moves the needle depends on whether investors believe governance matters more than growth right now.
So what's the real story here—is the market in trouble or just taking a breath?
That's the question everyone's asking. Technically, a temporary reprieve is possible. But the upside stays capped until banking and IT recover. Those two sectors are the market's heartbeat. Until they stabilize, everything else is just noise.